Gordon C. Weir, M.D.

Gordon C. Weir, M.D.

Joslin Diabetes Center
Harvard Medical School
Gordon Weir.

Dr. Gordon Weir has combined a career of caring for patients with diabetes with an intensive research focus on beta-cell replacement therapy.

One of the most important goals of diabetes research is to find sources of new beta cells (the islet cells in the pancreas that produce insulin) and to successfully transplant these cells into the pancreas. Weir's research interests include islet-cell transplantation and the function of islets in the normal and diabetic state.

The Weir laboratory has four quests:

  1. to understand the mechanisms that affect beta cells during diabetes;
  2. to new beta cells for transplantation;
  3. to perfect the procedures of beta-cell transplantation; and
  4. to protect transplanted beta cells from destruction.

To find the mechanisms affecting beta cells in diabetes, Weir and his colleagues use gene expression and microarrays to determine the unique “machinery” of the normally functioning beta cell so they can understand what happens to beta cells stressed by the diabetic state.

A second area of interest—developing an alternative source of insulin-producing cells—is driven by the shortage of human donor pancreases. Dr. Weir, Susan Bonner-Weir, Ph.D., and Arun Sharma, Ph.D., at Joslin are working with embryonic stem cells and adult precursor cells that have the capacity to become insulin-secreting cells.

Dr. Weir also collaborates with other scientists to establish a Harvard-wide effort to promote stem cell research. In addition, his group is investigating the use of genetic manipulation to convert liver cells into beta cells.

As part of the effort to improve islet-cell transplantation, Weir serves as Director of the Clinical Islet Transplantation Program at Harvard Medical School. This team performed successful transplants on patients with type 1 diabetes, some of whom had a kidney transplant and others who did not.

A complementary project is an effort to protect transplanted islet cells from destruction by the immune system. Weir and colleagues at the Massachusetts Institute of Technology have developed methods that use encapsulation and gene therapy. With encapsulation, islet cells are enclosed in a capsule with a gel-like membrane that prevents immune cells from reaching and destroying the islet cells inside. Current efforts are focused on ways to improve the health and efficiency of insulin-producing cells contained within these capsules.


Gordon Weir is a member of the Section on Islet and Regenerative Biology and Director of the Center for Cell Transplantation at the Joslin Diabetes Center, holds the Diabetes Research and Wellness Foundation Chair at Joslin, and is Professor of Medicine at Harvard Medical School. He received his medical degree from Harvard Medical School in 1967. Before coming to Joslin, Dr. Weir was Professor of Medicine at the Medical College of Virginia. After arriving at Joslin in 1984, Dr. Weir served as the Center's Medical Director for nine years and, throughout, has been conducting a broad research program.

Feature stories

Slight Elevations in Blood Glucose Lead to Key Changes in Beta-Cell Behavior

A better way to encapsulate islet cells for diabetes treatment

Research Interest(s)